5 results about "Signalling cascade" patented technology

This disclosure provides a method for alleviating aluminum toxicity in hydroponic peas based on menadione-mediated reactive oxygen species (ROS) metabolism. The core components include: regulating the concentration and duration of menadione treatment to optimize the spatiotemporal accumulation pattern of ROS (superoxide anion, hydrogen peroxide) in the roots of hydroponic peas; adjusting the dynamic response of endogenous antioxidant enzyme systems (SOD, POD, APX) to enhance menadione-mediated ROS scavenging capacity; controlling the initial ROS burst based on changes in plasma membrane NADPH oxidase (Rboh) gene expression and enzyme activity to inhibit the aluminum stress oxidative signaling cascade; and adjusting the timing and frequency of menadione administration based on subcellular-scale mitochondrial and chloroplast ROS leakage rates to alleviate organ-specific oxidative damage. This approach addresses five key issues: aluminum-induced oxidative damage, cellular redox imbalance, oxidative signaling cascade, organ-specific oxidative damage, and persistent aluminum toxicity metabolic disorders.

The present invention is directed to novel modulators of the Ca2+-signaling cascade, acting as potentiators of the P2RY2 purinergic receptor and of the inositol triphosphate receptors, ITPRs. The compounds are useful in the treatment of diseases and conditions in which modulation of Ca2+-signaling plays a role, such as in some forms of spinocerebellar ataxia, and in diseases and conditions benefiting from mucosal hydration, as for example respiratory diseases and conditions, dry eye, xerostomia.

This invention relates to a double-antibody sandwich ELISA kit for detecting serum PTGS1 protein, comprising: a PTGS1 capture antibody, an unlabeled PTGS1 detection antibody, an enzyme-labeled IgG secondary antibody, a solid-phase carrier, an enzyme substrate, a blocking buffer, a washing buffer, and a stop solution; the IgG secondary antibody specifically binds to the PTGS1 detection antibody; the PTGS1 capture antibody is a rabbit monoclonal antibody that specifically binds to the linear epitope A of human PTGS1 protein, the amino acid sequence of which is SEQ ID NO:1, corresponding to amino acids 271-282 of human PTGS1 protein; the PTGS1 detection antibody is a mouse monoclonal antibody that specifically binds to the B epitope of human PTGS1 protein; the amino acid sequences of the B epitope at the A epitope do not overlap and do not constitute steric hindrance. This kit avoids the conserved homologous region between PTGS1 and its homologous protein PTGS2, ensuring the accuracy of the capture antibody recognition, and uses an indirect detection mode with enzyme-labeled goat anti-mouse IgG secondary antibody to achieve signal cascade amplification, significantly improving detection sensitivity.

The present application relates to the field of nucleic acid detection, and particularly relates to a novel nucleic acid detection method based on CRISPR-Cas12. By introducing chemical modification (such as locked nucleic acid modification), the present application constructs a method for site-specific cleavage of specific phosphodiester bonds in single-stranded nucleic acid by Cas protein containing RuvC domain and a method for detecting target DNA in a sample to be tested, so as to realize site-specific cleavage and trigger signal cascade amplification, and then realize rapid and high-sensitivity detection of nucleic acid.

The application discloses application of ENOPH1 gene and relates to the technical field of biological medicine. In the application, bioinformatics analysis is adopted to identify key metabolic genes closely related to CRC prognosis, and expression of ENOPH1 in KRAS mutant CRC tissues and cell lines is evaluated. Through in vitro experiments such as CCK8, wound healing experiment and subcutaneous xenotransplant tumor model in vivo, the function of ENOPH1 in KRAS G12D / G13D mutant CRC is verified. The results show that ENOPH1 is highly expressed in KRAS mutant CRC and is controlled by MEK / ERK signal cascade. Through shRNA knockdown of ENOPH1, the proliferation, migration and tumorigenesis of CRC cells can be inhibited, cell apoptosis can be induced, and the response to chemotherapy can be enhanced. The application provides a new strategy and direction for the treatment of colorectal cancer, has extremely high clinical application value, and can bring better treatment effect for patients with intestinal cancer.